Inhalon Biopharma Completes IND-Enabling Studies for RSV Therapy IN-002

Inhalon Biopharma, Inc. (Inhalon), a clinical-stage firm developing a pioneering inhaled antibody platform for addressing acute respiratory infections (ARI), has today revealed the successful conclusion of IND-enabling studies for its respiratory syncytial virus (RSV) candidate, IN-002, with intentions to move its inhaled-antibody therapy into a human challenge study by 2026. The firm also revealed a contract with hVIVO (AIM: HVO), a rapidly advancing specialized contract research organization and the global leader in human challenge trials, to perform the Phase 2a trial.

Inhalon’s RSV candidate is among multiple potential treatments being created utilizing the firm's inhaled antibody technology for acute respiratory infections. The inhalation method administers therapeutic antibodies straight to the infection site in the airways with a handheld nebulizer, instead of using oral or intravenous dosing. Various animal studies have demonstrated that the inhaled treatment method is significantly more effective in addressing respiratory infections, suggesting it could lower costs and lessen the care burden on both patients and the healthcare system.

A previous clinical investigation1 that compared an inhaled antibody treatment developed by Inhalon with an antibody therapy sanctioned for intravenous delivery showed that Inhalon’s antibodies retain their complete efficacy after nebulization and can be administered consistently throughout the respiratory system, encompassing the deep lung. The research discovered that the levels of the antiviral antibody in the respiratory tracts of participants who were administered inhaled doses were 30-fold to 100-fold greater than those administered intravenously, even though the inhaled dose recipients received as much as 90% fewer antibodies.